Friday 6 November 2026
Export ATR’s income statement to Excel — free account
AptarGroup, Inc.
ATR Healthcare Medical Instruments & Supplies
AptarGroup, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.8 billion, up 5.42% from fiscal 2024.
- Revenue
- +6.03%
- EPS
- −73.9%
- Free cash flow
- −16.9%
- Total debt
- +14.6%
Quarter to September 2026, against a year earlier
143.84
3.02
−2.06%
Follow ATR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
29.13 | 22.36 | 21.32 | 20.43 |
+8 more quarters Free account |
P/S ratio |
1.93 | 2.03 | 2.08 | 2.12 | |
P/FCF ratio |
26.09 | 25.33 | 24.56 | 26.90 | |
P/Operating CF |
45.92 | 76.99 | 68.00 | 43.65 | |
P/B ratio |
2.92 | 3.01 | 3.05 | 2.99 | |
Price to Tangible BV |
5.74 | 5.93 | 6.07 | 5.93 | |
EV/Sales |
2.22 | 2.32 | 2.38 | 2.41 | |
EV/EBITDA |
11.32 | 11.65 | 11.62 | 11.53 | |
EV/Operating CF |
15.45 | 15.66 | 15.20 | 15.95 | |
EV/FCF |
30.03 | 29.05 | 28.02 | 30.50 | |
Quick Ratio |
0.90 | 0.96 | 1.00 | 1.04 | |
Current Ratio |
1.50 | 1.61 | 1.66 | 1.62 | |
Net Debt/EBITDA |
5.52 | 5.67 | 6.20 | 5.87 | |
Debt/Assets |
26.91% | 26.64% | 26.79% | 28.23% | |
Debt/Equity |
0.52 | 0.52 | 0.52 | 0.55 | |
Asset Turnover |
0.78 | 0.79 | 0.80 | 0.78 | |
Operating CF/Net income |
5.14 | 1.18 | 1.63 | 2.47 | |
Capex/Depreciation |
(0.94) | (0.71) | (0.85) | (1.12) | |
Interest Coverage |
8.55 | 7.92 | 6.34 | 6.25 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
15.72% | 15.37% | 17.05% | 15.72% | |
Intangible Assets out of Total Assets |
0.25 | 0.25 | 0.26 | 0.25 | |
Share Based Compensation of Revenue |
0.88% | 0.71% | 1.71% | 0.74% | |
Graham Net Nets |
(0.08) | (0.08) | (0.08) | (0.08) | |
Graham Number |
62.29 | 72.39 | 74.14 | 74.08 | |
Earnings Yield |
3.43% | 4.47% | 4.69% | 4.90% | |
Free Cash Flow Yield |
3.83% | 3.95% | 4.07% | 3.72% | |
Revenue per Share |
16.04 | 16.13 | 15.35 | 14.64 | |
Operating CF per Share |
2.64 | 1.63 | 1.85 | 2.79 | |
Capex per Share |
(1.12) | (0.89) | (1.01) | (1.31) | |
Free Cash Flow per Share |
1.52 | 0.74 | 0.84 | 1.48 | |
Cash per Share |
3.34 | 3.10 | 3.58 | 6.23 | |
Shareholders Equity per Share |
41.45 | 41.59 | 41.34 | 40.86 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
41.45 | 41.59 | 41.34 | 40.86 | |
Free Cash Flow |
96.46 | 46.93 | 54.03 | 97.60 | |
Working Capital |
613.98 | 698.27 | 705.24 | 727.12 | |
Capital Expenditures |
(71.14) | (56.56) | (64.66) | (86.09) | |
Net Current Asset Value |
(641.70) | (651.67) | (681.95) | (673.18) | |
EV/EBIT |
18.63 | 19.14 | 18.60 | 18.14 | |
Capex to Sales |
0.07 | 0.06 | 0.07 | 0.09 | |
Price to Operating Income |
16.19 | 16.69 | 16.30 | 16.00 | |
| Other line items | |||||
Average Receivables |
841.48 | 848.94 | 787.99 | 730.94 | |
Average Payables |
858.38 | 852.33 | 801.75 | 776.45 | |
Average Inventory |
564.95 | 553.78 | 517.50 | 499.83 | |
Average Assets |
5,106.24 | 4,999.30 | 4,812.44 | 4,842.50 | |
Average Common Equity |
2,710.34 | 2,682.27 | 2,599.55 | 2,585.95 |
Columns are period end dates · fundamentals updated 5 Nov 2026